Drug Type Small molecule drug |
Synonyms Ferric maltol (USAN/INN), Iron (III) maltol, ST-10 + [4] |
Target- |
Action- |
Mechanism Iron replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (18 Feb 2016), |
Regulation- |
Molecular FormulaC18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS Registry33725-54-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10833 | Ferric Maltol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Iron-Deficiency | Switzerland | 22 Sep 2017 | |
Iron deficiency | European Union | 18 Feb 2016 | |
Iron deficiency | Iceland | 18 Feb 2016 | |
Iron deficiency | Liechtenstein | 18 Feb 2016 | |
Iron deficiency | Norway | 18 Feb 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 3 | United Kingdom | 30 May 2022 | |
Colonic Cancer | Phase 3 | United Kingdom | 30 May 2022 | |
Chronic Kidney Diseases | Phase 3 | United States | 01 Dec 2016 | |
Colitis, Ulcerative | Phase 3 | - | 01 Aug 2011 | |
Crohn Disease | Phase 3 | - | 01 Aug 2011 |
Not Applicable | - | hzdutgltyi(jukzhwcgkb) = At the time of the current analysis, all 27 completed pregnancies proceeded without complications and ended with healthy neonatal infants without abnormalities. Two patients were still pregnant, with births expected in April /May 2023. wocfiqkgjh (ehtgxatiqi ) View more | - | 15 Oct 2023 | |||
Not Applicable | - | torhbjjoyo(qhhnerwjfn) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. smqhkvcyyn (zzintgdqtk ) | - | 02 Oct 2021 | |||
Phase 3 | 167 | inwsbovzie(uozijxcqcn): P-Value = 0.01 View more | Positive | 21 May 2021 | |||
Placebo | |||||||
Phase 1 | 37 | (30 mg Ferric Maltol) | ljzgxfmprx(ftuatwawnz) = mmtusgiluo ewcalnzgzs (xlsjhfuznq, 1.29590) View more | - | 02 Jun 2020 | ||
(16.6 mg Ferric Maltol) | ljzgxfmprx(ftuatwawnz) = ktxtocifih ewcalnzgzs (xlsjhfuznq, 0.18435) View more | ||||||
Phase 3 | 167 | (Oral Ferric Maltol) | zjzhmwqjqp(izrntefqkk) = huqwmmuryw xqdstdpeat (dalwwzluoe, 0.122) View more | - | 01 May 2020 | ||
Placebo (Oral Placebo) | zjzhmwqjqp(izrntefqkk) = wocrntvpgt xqdstdpeat (dalwwzluoe, 0.165) View more | ||||||
Phase 3 | 250 | (Oral Ferric Iron Compound) | bqjmoqaitd: Risk Difference (RD) = -0.17 (95% CI, -0.28 to -0.06), P-Value = 0.298 View more | - | 24 Feb 2020 | ||
(Intravenous Iron) | |||||||
Phase 3 | Inflammatory Bowel Diseases haemoglobin | ferritin | transferrin saturation | - | Oral ferric maltol 30 mg twice daily | ougsiqbdcz(ogbcleyzid) = oetyghlenk bzunuwcfoe (ezdslqkrqk ) | Positive | 21 Oct 2019 | |
Intravenous ferric carboxymaltose | ougsiqbdcz(ogbcleyzid) = qzzhybcvkl bzunuwcfoe (ezdslqkrqk ) | ||||||
Phase 3 | 167 | Oral Ferric Maltol (FM) 30 mg | lnqsxttugx(ngacihovpd) = Two patients died (one in each group), both considered unrelated to study drug dhlayynmxx (ypcfbqtwpk ) View more | Positive | 23 Oct 2018 | ||
Phase 3 | - | xaqjselmff(plvythsids) = yamtqwfblh jtuyldluys (ehjtekczgh ) View more | Positive | 23 Oct 2018 | |||
Placebo | xaqjselmff(plvythsids) = wxzwbzgdse jtuyldluys (ehjtekczgh ) View more | ||||||
Phase 3 | 128 | (ST10) | vhnmiiegtu(nczprgccmj) = zdphzeqoex mxlhoxzegu (ixrpchdhnh, 1.184) View more | - | 03 Aug 2018 | ||
Placebo Comparator (Placebo) | vhnmiiegtu(nczprgccmj) = ycihvwbocw mxlhoxzegu (ixrpchdhnh, 0.764) View more |